Neuphoria Therapeutics Inc. (NEUP) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.77

From 52W high−81.50%

Volume21578.00

Market cap$20.00M

P/E (TTM)—

P/S (TTM)−1.9x

Div yield—

Key dataSep 18, 2026

Open

$3.77

From 52W high

−81.50%

Volume

21578.00

Market cap

$20.00M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.0x

P/E (TTM)

—

RSI (14)

47.4

MomentumView details →

1D Return

−0.40%

YTD Return

−2.96%

SummaryUpdated Jun 1, 2026

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) is a clinical-stage biotechnology company founded on December 23, 2024, and headquartered in Burlington, Massachusetts. The company went public on December 16, 2021, and focuses on developing innovative therapies for individuals affected by neuropsychiatric disorders. As a relatively new entrant in the biotechnology sector, Neuphoria represents the emerging wave of specialized pharmaceutical companies targeting the complex intersection of neurology and psychiatry, an area that has historically been underserved by traditional drug development approaches.

Ask drillr about Neuphoria Therapeutics Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.0x

EV/Sales

−0.1x

P/S (TTM)

−1.9x

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

104.75%

Net Margin

271.97%

EBITDA Margin

217.07%

ROE (TTM)

−96.80%

ROA (TTM)

−81.82%

Asset Turnover

−0.29x

GrowthView details →

Revenue YoY

—

EPS YoY

+51.47%

FCF YoY

+9025.02%

Revenue CAGR 3Y

+244.38%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−0.40%

YTD Return

−2.96%

1Y Return

−62.72%

RSI (14)

47.4

vs 50D SMA

+0.17%

vs 200D SMA

−11.43%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

14.31x

Quick Ratio

14.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.56

EPS Surprise

0.00%

Beats (12Q)

4/12

Next Q EPS Est

−$1.58

Avg Surprise (4Q)

−387.95%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

−10.47M

Net Income (TTM)

−28.48M

Op. CF (TTM)

59.46M

Next earningsOct 5, 2026 →

Latest newsMore news →

Scancell Holdings plc announces an all-share merger to acquire Neuphoria Therapeutics Inc., with the combined company to operate as Scancell and trade on Nasdaq under the symbol SCLT.59d ago

Neuphoria Therapeutics is in talks with Scancell Holdings plc about a possible combination.86d ago

Similar companies

Hoth Therapeutics, Inc.RKTO AIxCrypto Holdings, Inc.AIXC Plus Therapeutics, Inc.CNSY Pa Shun International Holdings Limited00574.HK Kyntra Bio, Inc.KYNB Sanai Health Industry Group Company Limited01889.HK Find similar companies →

Latest newsMore news →

Scancell Holdings plc announces an all-share merger to acquire Neuphoria Therapeutics Inc., with the combined company to operate as Scancell and trade on Nasdaq under the symbol SCLT.59d ago Neuphoria Therapeutics is in talks with Scancell Holdings plc about a possible combination.86d ago